Idorsia Implements Veeva Development Cloud in Less Than 12 Months
July 10 2018 - 7:03AM
Business Wire
Unified applications for clinical, regulatory,
and quality help fast-growing start-up drive greater efficiency and
compliance throughout development
Veeva Systems (NYSE:VEEV) today announced that Idorsia
Pharmaceuticals Ltd established an integrated development landscape
with Veeva Development Cloud. With unified applications for
clinical, regulatory, and quality on a single cloud platform,
Idorsia now has the technology foundation to accelerate product
innovation and support its global growth plans.
“With a strong pipeline of innovative new therapies, we needed
cutting-edge cloud technology that could scale as we grow,” said
Joseph Bejjani, CIO at Idorsia. “Our IT strategy had three guiding
principles when it came to product selection – cloud-first,
easy-to-use functionality, and integrated, platform-based
solutions. Veeva met all three objectives within a very tight
timeline.”
Idorsia is a fast-growing biopharmaceutical start-up focused on
research and early-stage clinical development. Immediately after
its founding, Idorsia set an aggressive timeline to transition to
new clinical development systems within 12 months.
With Veeva Development Cloud, Idorsia has unified applications
to streamline documents and workflows so teams have a single source
of truth across clinical, regulatory, and quality. This eliminates
manual, duplicative efforts and gives teams consistent information
throughout development. Because Veeva Vault applications have the
same modern and intuitive interface, teams work with greater speed
and spend less time on training.
“Veeva gives us the right technology foundation to manage
business processes, content, and data across the organization,”
said Simone Mechler, associate director clinical & quality
systems. “We exceeded our goal and went live within seven months.
All regions and departments now have a consistent view of the
products in development to drive greater operational efficiency and
maintain compliance.”
Idorsia is using or plans to use multiple applications across
Veeva Development Cloud suites, including Vault eTMF and Vault CTMS
from Vault Clinical Suite; Vault Registrations, Vault Submissions,
and Vault Submissions Publishing from Vault RIM Suite; and Vault
QMS and Vault QualityDocs from Vault Quality Suite.
“Idorsia needed to bring together their applications for
clinical, quality, and regulatory to streamline drug development,”
said Rik Van Mol, vice president, R&D strategy, Europe at
Veeva. “Veeva Development Cloud helps life sciences companies like
Idorsia achieve alignment across headquarters, sites, and countries
and increase communication, collaboration, and compliance across
the functions.”
Additional Information
For more about Veeva Development Cloud, visit:
veeva.com/VeevaDevelopmentCloud
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the
global life sciences industry. Committed to innovation, product
excellence, and customer success, Veeva has more than 625
customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices in Europe, Asia, and Latin
America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the
market demand for and acceptance of Veeva’s products and services,
the results from use of Veeva’s products and services, and general
business conditions, particularly in the life sciences industry.
Any forward-looking statements contained in this press release are
based upon Veeva’s historical performance and its current plans,
estimates, and expectations, and are not a representation that such
plans, estimates, or expectations will be achieved. These
forward-looking statements represent Veeva’s expectations as of the
date of this press announcement. Subsequent events may cause these
expectations to change, and Veeva disclaims any obligation to
update the forward-looking statements in the future. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual results to differ
materially. Additional risks and uncertainties that could affect
Veeva’s financial results are included under the captions, “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on
Form 10-Q for the period ended
April 30, 2018. This is available on the company’s website at
veeva.com under the Investors section and on the SEC’s website at
sec.gov. Further information on potential risks that could affect
actual results will be included in other filings Veeva makes with
the SEC from time to time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180710005256/en/
Veeva SystemsRoger Villareal,
925-264-8885roger.villareal@veeva.comorLisa Barbadora,
610-420-3413pr@veeva.com
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Sep 2023 to Sep 2024